Literature DB >> 16606448

Disability weights for comorbidity and their influence on health-adjusted life expectancy.

Pieter H M van Baal1, Nancy Hoeymans, Rudolf T Hoogenveen, G Ardine de Wit, Gert P Westert.   

Abstract

BACKGROUND: Comorbidity complicates estimations of health-adjusted life expectancy (HALE) using disease prevalences and disability weights from Burden of Disease studies. Usually, the exact amount of comorbidity is unknown and no disability weights are defined for comorbidity.
METHODS: Using data of the Dutch national burden of disease study, the effects of different methods to adjust for comorbidity on HALE calculations are estimated. The default multiplicative adjustment method to define disability weights for comorbidity is compared to HALE estimates without adjustment for comorbidity and to HALE estimates in which the amount of disability in patients with multiple diseases is solely determined by the disease that leads to most disability (the maximum adjustment method). To estimate the amount of comorbidity, independence between diseases is assumed.
RESULTS: Compared to the multiplicative adjustment method, the maximum adjustment method lowers HALE estimates by 1.2 years for males and 1.9 years for females. Compared to no adjustment, a multiplicative adjustment lowers HALE estimates by 1.0 years for males and 1.4 years for females.
CONCLUSION: The differences in HALE caused by the different adjustment methods demonstrate that adjusting for comorbidity in HALE calculations is an important topic that needs more attention. More empirical research is needed to develop a more general theory as to how comorbidity influences disability.

Entities:  

Year:  2006        PMID: 16606448      PMCID: PMC1523368          DOI: 10.1186/1478-7954-4-1

Source DB:  PubMed          Journal:  Popul Health Metr        ISSN: 1478-7954


Background

Health-adjusted life expectancy (HALE) is a summary measure of population health that has been introduced as part of the Health Expectancy Network (Réseau Espérance de Vie en Santé, or REVES) and is defined as: "a generic term for a weighted expectation of life summed over a complete set of health states" [1]. HALE, like life expectancy, is independent of the size and composition of the population and is therefore useful to make comparisons between populations and over time [2]. One method of estimating HALE is by using data available from Burden of Disease studies [3]. As a first step to estimate HALE from Burden of Disease data, disease prevalences are coupled to disease specific disability weights to estimate the average amount of disability in a population specified by sex and age [4]. Disability weights reflect the relative severity and impact of a disease and theoretically range from 0 (no disability) to 1 (death) [5]. Then, the average amount of disability can be combined with a life table to estimate HALE. In this paper, we will focus on this specific form of HALE that has also been termed disability-adjusted life expectancy (DALE) [3,4]. Comorbidity, defined as the presence of two or more diseases in one person, complicates HALE calculations for two reasons. The first one is that the exact amount of comorbidity is unknown since all data on disease incidence, prevalence and mortality gathered in Burden of Disease (BOD) studies are disease specific [6]. The second reason is that there are no disability weights defined for comorbidity [6]. In a previous study, Barendregt and Bonneux found that HALE was generally insensitive to different methods to define disability weights for comorbidity [7]. However, they limited their research to six diseases and to comorbidity between disease pairs only. In this article, we will examine the impact of different methods to define disability weights for comorbidity on HALE estimates and compare them with HALE estimations without adjustment for comorbidity. If burden of disease data and disability weights are used for calculations of HALE, disability weights for comorbidity are usually calculated assuming a multiplicative model [4,8]. The multiplicative model implies that disability increases with the number of conditions one has, but that the overall effect is less than additive. This is in line with findings of Verbrugge et al. [9]. They tested whether disability increased linearly with the number of chronic conditions individuals have and investigated whether there are interaction effects on disability for specific combinations of chronic diseases. They concluded that although disability increases as the number of chronic conditions increases, the marginal increase decreased as the number of conditions increases. However, they also found that in many cases the disability caused by having two diseases was not higher than having either one of the two diseases. This latter finding suggests that solely the disease that leads to most disability determines the total amount of disability in patients with multiple diseases. To investigate the effect of adjustments for comorbidity we estimated HALE using two different methods to define disability weights for comorbidity: - multiplicative adjustment method: using this method it is assumed that the impact on disability due to comorbidity is proportional. Although disability increases with additional diseases, it is less than the sum of disability weights for the individual diseases. This is the default method used in HALE calculations [4,8]; - maximum adjustment method: using this method the disability weight for comorbidity equals the disability weight of the disease with the highest disability weight. This adjustment for comorbidity can be thought of as a maximum adjustment since having multiple diseases only leads to more disability if individual diseases lead to more disability. The total amount of disability attributed to comorbidity is equal to the highest amount of disability associated with one of the concurrent diseases. To quantify the importance of comorbidity adjustments, we will use HALE estimates without adjustments for comorbidity as a comparator. In the next section, we describe how to estimate the average disability weight and HALE using the different adjustment methods if independence between diseases is assumed. Then, results of HALE estimates are presented. In the last section, implications of the results and directions for future research are discussed.

Methods

In order to estimate HALE we set up an abridged life table using mortality rates for the Netherlands from 1999 [10]. The number of life years obtained from the life table were multiplied by one minus the average disability weights: HALEhealth-adjusted life expectancy gender g age a Lnumber of life years lived between age a and a+5 for gender g Lnumber of life years lived after age 85 for gender g maverage disability weight between age a and a+5 for gender g maverage disability weight after age 85+ for gender g lnumber of survivors at age a in the life table cohort for gender g z last open-ended age interval in the life table Age and sex specific average disability weights are a function of disease specific prevalence rates and disability weights. In our study, data from the Dutch Burden of Disease Study was used to estimate average disability weights. The Dutch Burden of Disease Study estimated disability weights, using a large panel of experts and the person trade off method [11], and disease prevalence of 48 different disease categories [12]. All data used in our calculations (mortality rates, disease prevalences and disability weights) are available in Additional file 1. To estimate comorbidity prevalence, independence between diseases is assumed so the amount of comorbidity between disease 1 and 2 (the joint prevalence of diseases 1 and 2) is simply the product of their prevalence rates: p(1,2) joint prevalence of disease 1 and 2 p(d) joint prevalence of d diseases Gender-specific average disability weights were calculated using age classes of five years (0–4, 5–9, 10–14 to 85+). However, for notational simplicity, age and sex indices have been omitted in the notation.

No adjustment for comorbidity

When no adjustment for comorbidity is made the average disability weight can be calculated by simply adding up the disability caused by all diseases: m average disability weight pprevalence rate of disease d wdisability weight of disease d Making no adjustment for comorbidity is equivalent to assuming that effects of comorbidity on disability are additive. Thus, if a person has more than one disease his total disability weight equals the sum of the disability weights for those diseases. However, in this interpretation individual disability weights may add up to more than one. This cannot be interpreted in a plausible way because it would imply that more than one year of health is lost when living for one year with those diseases.

Multiplicative adjustment method

Using this method, it is assumed that the increase in disability due to comorbidity disability is proportional. Total disability for an individual having more diseases can be written as: w(1,2) disability weight of an individual with disease 1 and 2 w(d) disability weight of an individual with d diseases This implies that the disability due to comorbidity increases with more comorbid diseases but is less than the sum of individual disability weights for all comorbid diseases. If there are only 2 diseases the average disability weight assuming independence equals: m = 1 - (1 - p1) (1 - p2) + (1 - p2) p1 (1 - w1) + (1 - p1) p2 (1 - w2) + p1p2 (1 - w1) (1 - w2) = 1 - (1 - p1w1) (1 - p2w2)     (5) This can be generalized to d diseases:

Maximum adjustment method

Compared to having one disease, having two diseases only leads to more disability if the second disease causes more disability than the first one. Assuming that the diseases are ordered in terms of disability weights, e.g. w1≥w2≥w3............wsomeone who has disease 1 and 2 has a disability weight that equals that of w1 since disease 1 is worse than disease 2: In order to estimate average disability weights using this method the prevalence rate for which disease d has the highest disability weight must be estimated (denoted H). We can recursively define the prevalence rate H(see Appendix for a derivation): Hprevalence rate for which disease d has the highest disability weight The average disability weight can then be written as:

Comparing different methods to adjust for comorbidity

Compared to no adjustment, the multiplicative adjustment method results in a lower average disability weight but compared to the maximum adjustment method in a higher average disability weight: For d diseases:

Results

Figures 1 and 2 display the estimated average disability weights for men and women, using the different adjustment methods.
Figure 1

Average disability weights for men in the Netherlands 1999 using different methods to adjust for comorbidity.

Figure 2

Average disability weights for women in the Netherlands 1999 using different methods to adjust for comorbidity.

Average disability weights for men in the Netherlands 1999 using different methods to adjust for comorbidity. Average disability weights for women in the Netherlands 1999 using different methods to adjust for comorbidity. By definition, the maximum adjustment method results in the lowest estimate of the average disability weight and no adjustment for comorbidity in the highest estimate. The difference between the adjustment methods increases with age. This is caused by the higher amount of comorbidity in the elderly. At age 85 and over the difference in the average disability weight between the multiplicative adjustment method and no adjustment amounts to 0.11 for men and 0.14 for women. The difference between the multiplicative and maximum adjustment methods are 0.11 and 0.13 for respectively men and women aged 85 and over. Thus, the choice for adjustment method has more implications in an elderly population than in a younger population. Tables 1 and 2 display estimates of life expectancy and HALE. Life expectancy for Dutch males in 1999 was 75.9 years. Depending on the adjustment method for comorbidity, 65.7 to 67.9 years are considered healthy years. Females have a higher life-expectancy, and also a higher HALE. Independent of the method of adjustment, women's HALE, relative to life expectancy, is always lower than men's HALE. This reflects the fact that men more often than women die from lethal diseases with a short duration (e.g. lung cancer). At birth, the difference in HALE between the multiplicative and maximum adjustment method is 1.2 years for males and 1.9 years for females. For males, the difference in HALE between the multiplicative and maximum adjustment method declines from 1.2 years at birth to 1.0 at the age of 60. For females, the differences between the methods are somewhat larger. The difference of 1.9 years in HALE at birth between the multiplicative and maximum adjustment method declines to 1.6 at the age of 60. For both males and females at all ages, the differences between no adjustment and multiplicative adjustment are smaller than the differences between the multiplicative and maximum adjustment method.
Table 1

Life Expectancy (LE) and Health-adjusted Life Expectancy (HALE) for Dutch males, 1999

AgeLEHALE
No adjustmentMultiplicative adjustment methodMaximum adjustment method

075.965.766.767.9
1561.551.752.653.8
6019.413.514.415.4
Table 2

Life Expectancy (LE) and Health-adjusted Life Expectancy (HALE) for Dutch females, 1999

AgeLEHALE
No adjustmentMultiplicative adjustment methodMaximum adjustment method

081.068.569.971.8
1566.654.455.857.6
6023.815.817.118.7
Life Expectancy (LE) and Health-adjusted Life Expectancy (HALE) for Dutch males, 1999 Life Expectancy (LE) and Health-adjusted Life Expectancy (HALE) for Dutch females, 1999

Discussion and conclusion

In this study, two different methods to adjust for comorbidity in HALE calculations were compared to HALE estimates without adjustment for comorbidity. The methods differ in the manner in which disability weights for comorbid conditions were defined. The multiplicative adjustment method implies that comorbidity increases disability but that the effects are less than the sum of disability from the individual diseases. Using the maximum adjustment method, disability is solely determined by the most severe disease. Compared to no adjustment, a multiplicative adjustment lowers HALE estimates with 1.0 years for males and 1.4 years for females. The maximum adjustment methods lowers HALE estimates compared to the multiplicative adjustment with 1.2 years for males and 1.9 years for females. Thus, the differences in HALE resulting of differences in defining disability weights are larger than the differences between no adjustment and the multiplicative adjustment method. Although we think the differences in HALE resulting of the different methods to define disability weights are important, also uncertainly related to the estimation of the prevalence of each of the 48 diseases may cause substantial variations in the average disability weights and, therefore, on HALE estimates. However, it is difficult to quantify this uncertainty because uncertainty estimates around the disease prevalence are not available [12]. In an attempt to test the sensitivity of HALE for variations in prevalence rates we calculated HALE using the multiplicative adjustment method and increased all prevalence rates with 10%. This lowered HALE estimates with less than one year for both males and females. Contrary to our results, Barendregt and Bonneux found in a previous study that HALE was generally insensitive to different methods of weighing comorbidity [7]. However, they limited themselves to six diseases and to comorbidity between disease pairs only. In our study, all possible combinations of comorbidity between 48 diseases were investigated. The explanation for the difference in results between our study and the Barendregt and Bonneux study is straightforward: if more diseases are taken into account, there is more comorbidity, especially if comorbidity between all disease combinations is described. With a higher prevalence of comorbidity, the method used to adjust for comorbidity becomes more important. A crucial assumption in this paper is that of independence between diseases. Although this assumption may be violated in practice, it will not influence our conclusion that adjustments for comorbidity are important in HALE calculations. In fact, assuming independence probably underestimates the amount of comorbidity since the probability of getting different diseases is not independent due to clustering of diseases as a result of genetics, biological risk factors (e.g. blood pressure, cholesterol) environmental factors (e.g. air pollution) and lifestyle (e.g. smoking and drinking) [13,14]. Different methods to define disability weights for comorbidity can have important implications not only for the estimation of HALE itself but also on applications of HALE such as monitoring trends in health or as an aid in priority setting. Even if the same methodology to adjust for comorbidity is used consistently, the choice of the adjustment method might influence the manner in which HALE reacts to trends or interventions. For instance, when using the maximum adjustment method eliminating diseases with low disability weights has smaller or even no impact on HALE compared to the multiplicative adjustment method. Furthermore, both the maximum and multiplicative adjustment methods imply that in priority setting, ceteris paribus, less priority should be given to patients with more comorbidity. For example, improving diabetes care in diabetes patients without coronary heart disease results in a larger increase in average disability than diabetes care in patients with coronary heart disease. This latter example demonstrates that the choice for comorbidity adjustment might also have implications for equity trade-offs. Moreover, for the comparison of effects of specific interventions targeted at groups with different comorbidity prevalences (e.g. young and old), the choice of adjustment method may have a different impact for different interventions, and thus may affect the conclusion. The problems caused by comorbidity in HALE calculations are not present if self reported generic measures of health such as the EQ-5D are used. [15-17] Then, patients decide for themselves how the total disability that is caused by all concurrent diseases influences their functioning and quality of life. Therefore, empirical results of studies using self reported generic measures could be used to develop a more general theory as to how comorbidity influences disability. For instance, a question that needs to be answered is whether two comorbid diseases from different "disease clusters" (such as a physically limiting disease combined with a mental disease) leads to more disability than two or more diseases from one "disease cluster". Such a theory might be used to justify the choice for a specific adjustment method in HALE calculations.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

PHMvB carried out the analyses and drafted the manuscript. RTH contributed to the mathematics. NH provided the data. All authors contributed to the writing of the paper.

Appendix: derivation of average disability weights for maximum adjustment method

The fraction of the population that gets the weight of disease d equals the prevalence rate of disease d minus the fraction of the population that has disease d but also a disease with a higher disability weight. Assuming that the diseases are ordered in terms of disability weights, e.g. w1≥w2≥w3 .....................wwe can write this principle for three diseases as: H1 = p1 H2 = p2 *(1 - p1) H3 = p3 *(1 - (p1 + p2 - p2 * p2)) Hprevalence rate for which disease d has the highest disability weight pprevalence rate of disease d This can be rewritten to: H1 = p1 H2 = (1 - H1) p2 H3 = (1 - H1 - H2) p3 Using this we can recursively define the prevalence rate H: The average disability weight can then be written as: m average disability weight wdisability weight of disease d Click here for file
  12 in total

1.  A national burden of disease calculation: Dutch disability-adjusted life-years. Dutch Burden of Disease Group.

Authors:  J M Melse; M L Essink-Bot; P G Kramers; N Hoeymans
Journal:  Am J Public Health       Date:  2000-08       Impact factor: 9.308

Review 2.  Causes and consequences of comorbidity: a review.

Authors:  R Gijsen; N Hoeymans; F G Schellevis; D Ruwaard; W A Satariano; G A van den Bos
Journal:  J Clin Epidemiol       Date:  2001-07       Impact factor: 6.437

Review 3.  A critical examination of summary measures of population health.

Authors:  C J Murray; J A Salomon; C Mathers
Journal:  Bull World Health Organ       Date:  2000       Impact factor: 9.408

4.  Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey.

Authors:  Sheri L Maddigan; David H Feeny; Jeffrey A Johnson
Journal:  Qual Life Res       Date:  2005-06       Impact factor: 4.147

5.  Comorbidity and its impact on disability.

Authors:  L M Verbrugge; J M Lepkowski; Y Imanaka
Journal:  Milbank Q       Date:  1989       Impact factor: 4.911

6.  Quantifying the burden of disease: the technical basis for disability-adjusted life years.

Authors:  C J Murray
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

7.  The burden of disease and injury in Australia.

Authors:  C D Mathers; E T Vos; C E Stevenson; S J Begg
Journal:  Bull World Health Organ       Date:  2001       Impact factor: 9.408

8.  Healthy life expectancy in 191 countries, 1999.

Authors:  C D Mathers; R Sadana; J A Salomon; C J Murray; A D Lopez
Journal:  Lancet       Date:  2001-05-26       Impact factor: 79.321

9.  Risk factors for 12-month comorbidity of mood, anxiety, and substance use disorders: findings from the Netherlands Mental Health Survey and Incidence Study.

Authors:  Ron de Graaf; Rob V Bijl; Filip Smit; Wilma A M Vollebergh; J Spijker
Journal:  Am J Psychiatry       Date:  2002-04       Impact factor: 18.112

Review 10.  Multimorbidity and quality of life in primary care: a systematic review.

Authors:  Martin Fortin; Lise Lapointe; Catherine Hudon; Alain Vanasse; Antoine L Ntetu; Danielle Maltais
Journal:  Health Qual Life Outcomes       Date:  2004-09-20       Impact factor: 3.186

View more
  17 in total

1.  The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population.

Authors:  Paul F van Gils; Eelco A B Over; Heleen H Hamberg-van Reenen; G Ardine de Wit; Matthijs van den Berg; Albertine J Schuit; Peter M Engelfriet
Journal:  BMJ Open       Date:  2011-12-21       Impact factor: 2.692

2.  A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000-2020).

Authors:  Hugo C Turner; Eric A Ottesen; Mark H Bradley
Journal:  Parasit Vectors       Date:  2022-05-28       Impact factor: 4.047

3.  Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.

Authors:  Lieven Annemans; Kristiaan Nackaerts; Pierre Bartsch; Jacques Prignot; Sophie Marbaix
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

4.  Three methods tested to model SF-6D health utilities for health states involving comorbidity/co-occurring conditions.

Authors:  Janel Hanmer; David Vanness; Ronald Gangnon; Mari Palta; Dennis G Fryback
Journal:  J Clin Epidemiol       Date:  2009-11-06       Impact factor: 6.437

5.  Burden of disease resulting from chronic mountain sickness among young Chinese male immigrants in Tibet.

Authors:  Tao Pei; Xiaoxiao Li; Fasheng Tao; Haotong Xu; Haiyan You; Linlin Zhou; Yan Liu; Yuqi Gao
Journal:  BMC Public Health       Date:  2012-06-06       Impact factor: 3.295

Review 6.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2015-06-07       Impact factor: 202.731

7.  The effect of comorbidity on health-related quality of life for injury patients in the first year following injury: comparison of three comorbidity adjustment approaches.

Authors:  Juanita A Haagsma; Ed F van Beeck; Suzanne Polinder; Hidde Toet; Martien Panneman; Gouke J Bonsel
Journal:  Popul Health Metr       Date:  2011-04-24

8.  Co-occurrence of diabetes, myocardial infarction, stroke, and cancer: quantifying age patterns in the Dutch population using health survey data.

Authors:  Pieter H van Baal; Peter M Engelfriet; Hendriek C Boshuizen; Jan van de Kassteele; Francois G Schellevis; Rudolf T Hoogenveen
Journal:  Popul Health Metr       Date:  2011-09-01

9.  Decomposing cross-country differences in quality adjusted life expectancy: the impact of value sets.

Authors:  Richard Heijink; Pieter van Baal; Mark Oppe; Xander Koolman; Gert Westert
Journal:  Popul Health Metr       Date:  2011-06-23

10.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Theo Vos; Abraham D Flaxman; Mohsen Naghavi; Rafael Lozano; Catherine Michaud; Majid Ezzati; Kenji Shibuya; Joshua A Salomon; Safa Abdalla; Victor Aboyans; Jerry Abraham; Ilana Ackerman; Rakesh Aggarwal; Stephanie Y Ahn; Mohammed K Ali; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Adil N Bahalim; Suzanne Barker-Collo; Lope H Barrero; David H Bartels; Maria-Gloria Basáñez; Amanda Baxter; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Eduardo Bernabé; Kavi Bhalla; Bishal Bhandari; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; James A Black; Hannah Blencowe; Jed D Blore; Fiona Blyth; Ian Bolliger; Audrey Bonaventure; Soufiane Boufous; Rupert Bourne; Michel Boussinesq; Tasanee Braithwaite; Carol Brayne; Lisa Bridgett; Simon Brooker; Peter Brooks; Traolach S Brugha; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Geoffrey Buckle; Christine M Budke; Michael Burch; Peter Burney; Roy Burstein; Bianca Calabria; Benjamin Campbell; Charles E Canter; Hélène Carabin; Jonathan Carapetis; Loreto Carmona; Claudia Cella; Fiona Charlson; Honglei Chen; Andrew Tai-Ann Cheng; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Manu Dahiya; Nabila Dahodwala; James Damsere-Derry; Goodarz Danaei; Adrian Davis; Diego De Leo; Louisa Degenhardt; Robert Dellavalle; Allyne Delossantos; Julie Denenberg; Sarah Derrett; Don C Des Jarlais; Samath D Dharmaratne; Mukesh Dherani; Cesar Diaz-Torne; Helen Dolk; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Karen Edmond; Alexis Elbaz; Suad Eltahir Ali; Holly Erskine; Patricia J Erwin; Patricia Espindola; Stalin E Ewoigbokhan; Farshad Farzadfar; Valery Feigin; David T Felson; Alize Ferrari; Cleusa P Ferri; Eric M Fèvre; Mariel M Finucane; Seth Flaxman; Louise Flood; Kyle Foreman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Richard Franklin; Marlene Fransen; Michael K Freeman; Belinda J Gabbe; Sherine E Gabriel; Emmanuela Gakidou; Hammad A Ganatra; Bianca Garcia; Flavio Gaspari; Richard F Gillum; Gerhard Gmel; Richard Gosselin; Rebecca Grainger; Justina Groeger; Francis Guillemin; David Gunnell; Ramyani Gupta; Juanita Haagsma; Holly Hagan; Yara A Halasa; Wayne Hall; Diana Haring; Josep Maria Haro; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Hideki Higashi; Catherine Hill; Bruno Hoen; Howard Hoffman; Peter J Hotez; Damian Hoy; John J Huang; Sydney E Ibeanusi; Kathryn H Jacobsen; Spencer L James; Deborah Jarvis; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Jost B Jonas; Ganesan Karthikeyan; Nicholas Kassebaum; Norito Kawakami; Andre Keren; Jon-Paul Khoo; Charles H King; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Ratilal Lalloo; Laura L Laslett; Tim Lathlean; Janet L Leasher; Yong Yi Lee; James Leigh; Stephen S Lim; Elizabeth Limb; John Kent Lin; Michael Lipnick; Steven E Lipshultz; Wei Liu; Maria Loane; Summer Lockett Ohno; Ronan Lyons; Jixiang Ma; Jacqueline Mabweijano; Michael F MacIntyre; Reza Malekzadeh; Leslie Mallinger; Sivabalan Manivannan; Wagner Marcenes; Lyn March; David J Margolis; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; Neil McGill; John McGrath; Maria Elena Medina-Mora; Michele Meltzer; George A Mensah; Tony R Merriman; Ana-Claire Meyer; Valeria Miglioli; Matthew Miller; Ted R Miller; Philip B Mitchell; Ana Olga Mocumbi; Terrie E Moffitt; Ali A Mokdad; Lorenzo Monasta; Marcella Montico; Maziar Moradi-Lakeh; Andrew Moran; Lidia Morawska; Rintaro Mori; Michele E Murdoch; Michael K Mwaniki; Kovin Naidoo; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Paul K Nelson; Robert G Nelson; Michael C Nevitt; Charles R Newton; Sandra Nolte; Paul Norman; Rosana Norman; Martin O'Donnell; Simon O'Hanlon; Casey Olives; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Andrew Page; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Scott B Patten; Neil Pearce; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; Konrad Pesudovs; David Phillips; Michael R Phillips; Kelsey Pierce; Sébastien Pion; Guilherme V Polanczyk; Suzanne Polinder; C Arden Pope; Svetlana Popova; Esteban Porrini; Farshad Pourmalek; Martin Prince; Rachel L Pullan; Kapa D Ramaiah; Dharani Ranganathan; Homie Razavi; Mathilda Regan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Kathryn Richardson; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Felipe Rodriguez De Leòn; Luca Ronfani; Robin Room; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Sukanta Saha; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; David C Schwebel; James Graham Scott; Maria Segui-Gomez; Saeid Shahraz; Donald S Shepard; Hwashin Shin; Rupak Shivakoti; David Singh; Gitanjali M Singh; Jasvinder A Singh; Jessica Singleton; David A Sleet; Karen Sliwa; Emma Smith; Jennifer L Smith; Nicolas J C Stapelberg; Andrew Steer; Timothy Steiner; Wilma A Stolk; Lars Jacob Stovner; Christopher Sudfeld; Sana Syed; Giorgio Tamburlini; Mohammad Tavakkoli; Hugh R Taylor; Jennifer A Taylor; William J Taylor; Bernadette Thomas; W Murray Thomson; George D Thurston; Imad M Tleyjeh; Marcello Tonelli; Jeffrey A Towbin; Thomas Truelsen; Miltiadis K Tsilimbaris; Clotilde Ubeda; Eduardo A Undurraga; Marieke J van der Werf; Jim van Os; Monica S Vavilala; N Venketasubramanian; Mengru Wang; Wenzhi Wang; Kerrianne Watt; David J Weatherall; Martin A Weinstock; Robert Weintraub; Marc G Weisskopf; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Sean R M Williams; Emma Witt; Frederick Wolfe; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Anita K M Zaidi; Zhi-Jie Zheng; David Zonies; Alan D Lopez; Christopher J L Murray; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.